COL18A1 and non-small cell lung carcinoma: Rh‐endostatin (rh‐endostatin) is a new and modified recombined human endostatin developed by Chinese scientist, which had been demonstrated to offer clinical benefits for patients with advanced NSCLC in several clinical trials.6, 16, 17, 18 Based on the encouraging outcomes in a large randomized, double‐blind phase III clinical trial,19 rh‐endostatin was approved by CFDA in combination with vinorelbine/cisplatin for patients with advanced NSCLC in 2005.